PMID- 21440948
OWN - NLM
STAT- MEDLINE
DCOM- 20120125
LR  - 20181201
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 93
IP  - 1
DP  - 2011 Jul
TI  - Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A 
      randomized, cross-over study.
PG  - e25-8
LID - 10.1016/j.diabres.2011.03.009 [doi]
AB  - A randomized, crossover study compared the effects of atorvastatin, gemfibrozil 
      and their combination on inflammatory markers in type 2 diabetes. C-reactive 
      protein (CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2), secretory 
      phospholipase A2 (sPLA2), interleukin 8 (IL8), monocyte chemotactic protein 1 
      (MCP1) and tumor necrosis factor alpha (TNFalpha) were measured. Both lipid-lowering 
      drugs had positive, complementary and additive effects on inflammatory markers, 
      which were closely related to baseline inflammatory status.
CI  - Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
FAU - Wagner, Ana Maria
AU  - Wagner AM
AD  - Endocrinology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
FAU - Sanchez-Quesada, Jose Luis
AU  - Sanchez-Quesada JL
FAU - Benitez, Sonia
AU  - Benitez S
FAU - Bancells, Cristina
AU  - Bancells C
FAU - Ordonez-Llanos, Jordi
AU  - Ordonez-Llanos J
FAU - Perez, Antonio
AU  - Perez A
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110326
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Fibric Acids)
RN  - 0 (Heptanoic Acids)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Pyrroles)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - A0JWA85V8F (Atorvastatin)
RN  - EC 3.1.1.4 (Phospholipases A2)
RN  - EC 3.1.1.4 (Phospholipases A2, Secretory)
RN  - EC 3.1.1.47 (1-Alkyl-2-acetylglycerophosphocholine Esterase)
SB  - IM
MH  - 1-Alkyl-2-acetylglycerophosphocholine Esterase/blood
MH  - Aged
MH  - Atorvastatin
MH  - C-Reactive Protein
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/*blood/*drug therapy
MH  - Female
MH  - Fibric Acids/*therapeutic use
MH  - Heptanoic Acids/therapeutic use
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Inflammation/*blood/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Phospholipases A2/blood
MH  - Phospholipases A2, Secretory/blood
MH  - Pyrroles/therapeutic use
EDAT- 2011/03/29 06:00
MHDA- 2012/01/26 06:00
CRDT- 2011/03/29 06:00
PHST- 2010/10/20 00:00 [received]
PHST- 2011/02/22 00:00 [revised]
PHST- 2011/03/01 00:00 [accepted]
PHST- 2011/03/29 06:00 [entrez]
PHST- 2011/03/29 06:00 [pubmed]
PHST- 2012/01/26 06:00 [medline]
AID - S0168-8227(11)00128-8 [pii]
AID - 10.1016/j.diabres.2011.03.009 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2011 Jul;93(1):e25-8. doi: 
      10.1016/j.diabres.2011.03.009. Epub 2011 Mar 26.